Jefferies says Australia's Healius may face tough FY23; raises PT

HL Science

30/08/2022 21:09

** Brokerage Jefferies lifts PT on Australian healthcare
firm Healius Ltd  HLS.AX  to A$4.40 from A$4.30
    ** HLS posted a more than sevenfold increase in FY22 profit
after tax to A$307.9 mln ($211.07 mln)  urn:newsml:reuters.com:*:nFWN3051CQ
    ** Co declared total dividend in FY22 of 16 Australian
cents, up from 13.25 cents last year
    ** Jefferies, however, says it worries that FY23 might be
tough for HLS
    ** Brokerage believes there are likely going to be impacts
from healthcare cost inflation and lower healthcare services
volumes at least into H2 FY23
    ** Jefferies expects margins on COVID-19 clinical lab tests 
to fall in FY23 and ahead, in line with lower volumes of testing
    ** Five of 14 analysts rate the stock "buy" or higher, eight
"hold" and one "sell"; their median PT is A$4.30 – Refinitiv
Eikon data 
    ** HLS down 27.5% YTD, as of last close 
    



($1 = 1.4588 Australian dollars)

 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))